Let’s Talk Turkey About Double Chins
Pharmaceuticals ▶ Allergan, which gave us Botox, rolls out a drug for droopy jowls ▶ “Now we’re almost a one-stop shop. We own the face”
Two decades ago, Allergan turned the dermatology world on its head with its wrinkle-reducing Botox. Now the company hopes to do the same with Kybella, the first injectable treatment for what doctors call “submental fat”— what the rest of us think of as the goop inside double chins. “It’s a disruptive technology,” says Philippe Schaison, president of Allergan’s U.S. medical business. “It’s working great, and there’s nothing like it.”
Soon after the Food and Drug Administration approved the chin treatment in April 2015, Allergan bought its developer, Kythera Biopharmaceuticals, for $2.1 billion. Since then it’s trained 1,600 U.S. and Canadian doctors to administer the drug. In September it will launch a marketing blitz including TV spots to woo double-chin-conscious consumers.
The active ingredient in Kybella, deoxycholic acid, is a form of bile that destroys fat cells in the digestive tract. It does the same in the chin. The